secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEXGEL, INC. (NXGL)
CIK:        0001468929
Form:       8-K
Filed at:   2022-11-08T23:59:59+00:00
Accession:  0001493152-22-030972
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NEXGEL Q3 revenue up 69.6% to $568k; gross margin improves to 26%
-----------------------------------------------------------------

- Revenue $568k, +69.6% YoY; growth driven by branded consumer products.
- Gross profit margin 26%, improved from negative margin in prior year; anticipates continued expansion.
- Operating expenses $1.2M include $220k one-time franchise tax; R&D spending increased to $193k from $0.
- Cash and marketable securities $7.4M; expects runway through 2024 to support R&D growth.
- Positive results from proof-of-concept study for diclofenac hydrogel pain patches; new proprietary amblyopia eye patch developed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1468929/000149315222030972/0001493152-22-030972-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1468929/000149315222030972/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-030972

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer